Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoshihiko Ichikawa

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Internal Medicine (Tokyo, Japan)|September 11, 2007
Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndromeYoshihiko Ichikawa
American Journal of Physiology. Heart and Circulatory Physiology|August 16, 2011
microRNA-210 is upregulated in hypoxic cardiomyocytes through Akt- and p53-dependent pathways and exerts cytoprotective effectsR Kannan Mutharasan, Varun Nagpal, Yoshihiko Ichikawa, et al.
Journal of the American College of Cardiology|October 18, 2002
K(ATP) channel opening is an endogenous mechanism of protection against the no-reflow phenomenon but its function is compromised by hypercholesterolemiaSatoshi Genda, Tetsuji Miura, Takayuki Miki, et al.
Angiology|April 16, 2002
Long-term follow-up after coronary stent implantation in patients with coronary artery diseaseHisataka Sasao, Akita Endo, Tohru Hasegawa, et al.
Cardiovascular Research|March 17, 2004
The role of ADAM protease in the tyrosine kinase-mediated trigger mechanism of ischemic preconditioningYoshihiko Ichikawa, Tetsuji Miura, Atsushi Nakano, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|September 19, 2002
Effects of neutral endopeptidase 24.11 inhibition on myocardial infarct size and ischemic preconditioning in rabbitsAtsushi Nakano, Tetsuji Miura, Takayuki Miki, et al.
Diabetes, Obesity & Metabolism|November 26, 2022
A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF-06882961), an oral small-molecule glucagon-like peptide-1 receptor agonist, in Japanese adults with type 2 diabetes mellitusRyosuke Ono, Kenichi Furihata, Yoshihiko Ichikawa, et al.
Cardiovascular Research|October 16, 2004
Role of microtubules in ischemic preconditioning against myocardial infarctionYuichi Nakamura, Tetsuji Miura, Atsushi Nakano, et al.
Molecular and Cellular Biochemistry|July 5, 2003
Interruption of signal transduction between G protein and PKC-epsilon underlies the impaired myocardial response to ischemic preconditioning in postinfarct remodeled heartsTakayuki Miki, Tetsuji Miura, Masaya Tanno, et al.
American Journal of Physiology. Heart and Circulatory Physiology|September 23, 2003
Protective role of gap junctions in preconditioning against myocardial infarctionTetsuji Miura, Yoshito Ohnuma, Atsushi Kuno, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Internal Medicine (Tokyo, Japan)|September 11, 2007
Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndromeYoshihiko Ichikawa
American Journal of Physiology. Heart and Circulatory Physiology|August 16, 2011
microRNA-210 is upregulated in hypoxic cardiomyocytes through Akt- and p53-dependent pathways and exerts cytoprotective effectsR Kannan Mutharasan, Varun Nagpal, Yoshihiko Ichikawa, et al.
Journal of the American College of Cardiology|October 18, 2002
K(ATP) channel opening is an endogenous mechanism of protection against the no-reflow phenomenon but its function is compromised by hypercholesterolemiaSatoshi Genda, Tetsuji Miura, Takayuki Miki, et al.
Angiology|April 16, 2002
Long-term follow-up after coronary stent implantation in patients with coronary artery diseaseHisataka Sasao, Akita Endo, Tohru Hasegawa, et al.
Cardiovascular Research|March 17, 2004
The role of ADAM protease in the tyrosine kinase-mediated trigger mechanism of ischemic preconditioningYoshihiko Ichikawa, Tetsuji Miura, Atsushi Nakano, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|September 19, 2002
Effects of neutral endopeptidase 24.11 inhibition on myocardial infarct size and ischemic preconditioning in rabbitsAtsushi Nakano, Tetsuji Miura, Takayuki Miki, et al.
Diabetes, Obesity & Metabolism|November 26, 2022
A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF-06882961), an oral small-molecule glucagon-like peptide-1 receptor agonist, in Japanese adults with type 2 diabetes mellitusRyosuke Ono, Kenichi Furihata, Yoshihiko Ichikawa, et al.
Cardiovascular Research|October 16, 2004
Role of microtubules in ischemic preconditioning against myocardial infarctionYuichi Nakamura, Tetsuji Miura, Atsushi Nakano, et al.
Molecular and Cellular Biochemistry|July 5, 2003
Interruption of signal transduction between G protein and PKC-epsilon underlies the impaired myocardial response to ischemic preconditioning in postinfarct remodeled heartsTakayuki Miki, Tetsuji Miura, Masaya Tanno, et al.
American Journal of Physiology. Heart and Circulatory Physiology|September 23, 2003
Protective role of gap junctions in preconditioning against myocardial infarctionTetsuji Miura, Yoshito Ohnuma, Atsushi Kuno, et al.
Pageof 2